凝血因子Ⅻ-抗血栓形成的新靶点  

Coagulation factorⅫ:a new target for antithrombotic drug

作　　者：杨鑫萍 连琪 余伯阳[1] 刘吉华[1] 刘秀峰[1] YANG Xinping;LIAN Qi;YU Boyang;LIU Jihua;LIU Xiufeng(Jiangsu Key Laboratory of Evaluation and Transformation of Traditional Chinese Medicine,Research Center for Traceability and Standardization of Traditional Chinese Medicine,China Pharmaceutical University,Nanjing 210009,China)

机构地区：[1]中国药科大学江苏省中药评价与转化重点实验室,中国药科大学中药可追溯与标准化研究中心,江苏南京210009

出　　处：《药学研究》2022年第11期731-736,共6页Journal of Pharmaceutical Research

基　　金：国家自然科学基金(No.82141207)。

摘　　要：随着血栓性疾病发病率的逐年上升,人类的健康受到了严重危害。目前常用治疗血栓的药物大都存在着出血风险。为寻求有效且能避免出血的抗血栓治疗靶点,凝血途径中每一个因子都被不同程度的开发。在这些因子中,凝血因子Ⅻ(factorⅫ,FⅫ)脱颖而出。大量研究表明,凝血因子Ⅻ的功能缺失可以抑制血栓形成而不会引起自发性出血。因此,本文以凝血因子Ⅻ作为抗血栓药物新靶点为主题,对凝血因子Ⅻ在血栓形成中的作用及其作为抗血栓药物靶点的研究进展做一综述。People′s health is under serious threat with the incidence of thrombotic diseases increasing year by year.Most of the drugs currently commonly used to treat thrombosis are associated with bleeding risks.Each factor in the clotting pathway has been developed to varying degrees in order to find effective antithrombotic therapeutic targets that can avoid bleeding.Among these factors,coagulation factorⅫ(FⅫ)stands out because numerous studies have shown that blocking FⅫ′s function prevents thrombosis without causing spontaneous bleeding.Therefore,with the theme of FⅫas a new target of antithrombotic drugs,this paper reviewed the role of FⅫin thrombosis and its research progress as a target of antithrombotic drugs.

关 键 词：血栓性疾病 凝血因子Ⅻ 抗血栓形成 新靶点 

分 类 号：R543.311[医药卫生—心血管疾病]